Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

Lung, Respiratory and Thoracic Cancer

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Lung Cancer

Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D

doi: 10.1016/j.lungcan.2024.107950

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Skin Cancer

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Eur J Cancer

Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, Ugurel S, Hausschild A, Meier F, Leiter U, Livingstone E, Gebhardt C, Gutzmer R, Ruhlmann CH, Mahncke-Guldbrandt L, Haslund CA, Kopec S, Teterycz P, Bender M, Poudroux W, Muñoz-Couselo E, Berciano-Guerrero MA, Shalamanova G, DePalo DK, Brozić JM, Chiarion-Sileni V, Arance A, Ziogas D, Robert C, van de Velde AO, Gassama AA, Shapira R, BenBetzalel G, Grynberg S, Ramelyte E, Bertoldo F, DelPrete V, Gaudy-Marqueste C, Mohr P, Dummer R, Ascierto PA, Gogas H, Espinosa E, Lebbé C, Rutkowski P, Haanen J, Schadendorf D, Svane IM, EUMelaReg Consortium Members

doi: 10.1016/j.ejca.2025.115339

Lung, Respiratory and Thoracic Cancer

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Lung Cancer

Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K

doi: 10.1016/j.lungcan.2025.108447

Lung, Respiratory and Thoracic Cancer

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Lung Cancer

Sugai M, Amino Y, Fujishima S, Nibuya K, Iso H, Ito M, Tsugitomi R, Ariyasu R, Uchibori K, Yanagitani N, Nishio M

doi: 10.1016/j.lungcan.2025.108555

Lung, Respiratory and Thoracic Cancer

Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights

Cancers (Basel)

Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X

doi: 10.3390/cancers16213563

Gastrointestinal Cancer

Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study

Eur J Cancer

Campo-Le-Brun I, Grapinet E, Aurillac V, Hollebecque A, Parent P, Girot P, Tougeron D, Gendreau M, Chanez B, Assenat E, Pernot S, Alouani E, Taieb J, Javed S, Touchefeu Y, Roth G, Muller M, Bachet JB, Lequoy M, Hautefeuille V, Ben-Abdelghani M, Masson T, Guimbaud R, Boilève A, Decraecker M

doi: 10.1016/j.ejca.2025.115670

Skin Cancer

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome

Eur J Cancer

Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, Schmidt H, Bastholt L, Ruhlmann CH, Svane IM, Ellebaek E

doi: 10.1016/j.ejca.2024.115053

Related content

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights

Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome